Skip to content

Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy

Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06309628
Enrollment
35
Registered
2024-03-13
Start date
2023-09-21
Completion date
2025-05-09
Last updated
2025-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Transplant Rejection

Brief summary

This study will sample and analyze volatile organic compounds (VOCs) from participants considered to be at risk for developing rejection following lung transplant by using infrared spectroscopy.

Detailed description

The aim of this study is to sample and analyze volatile organic compounds (VOCs) from participants considered to be at risk for developing rejection following lung transplant. By using infrared spectroscopy, the breath sample analysis will help investigators describe and identify patterns of VOCs that are over- or under-represented in patients with post-lung transplant rejection when compared to the breath profiles of those without rejection. It is hypothesized that the profile of volatile chemicals in the breath of patients in the early stages of rejection will differ significantly from those individuals without rejection. Primary objective • To analyze the breath-born VOCs in breath profiles of lung transplant patients with rejection in comparison to lung transplant patients without rejection using infrared spectroscopy to determine the presence of lung rejection and to develop mathematical/statistical models of infrared absorption spectrum for identification of rejection. Secondary objective * To determine the best method to classify health status based on VOC data of breath samples * To validate early test results on an additional infrared spectroscopic analyzer in post-lung transplant patients The study is an unblinded, prospective case-control study. The study cohorts will include: 1) patients with confirmed post-lung transplant rejection via biopsy, and 2) control patients who have undergone lung transplant but are free from rejection as confirmed via biopsy. Breath samples collected from participants will be analyzed to characterize and further identify differences in infrared absorption profiles from each cohort using infrared spectroscopy. The data will be used to validate a previously developed machine learning algorithm.

Interventions

DIAGNOSTIC_TESTBreathe sample

Patients will provide two breathe sample into the Breathe device to see if their VOC patterns can be used to diagnose lung transplant rejection.

Sponsors

Breathe BioMedical Inc
CollaboratorINDUSTRY
Paragonix Technologies
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 and older * Patient is able to give informed consent * Lung transplant patient who had both lungs transplanted * Patient is at least 90 days after their lung transplant * Patient is able to provide a breath sample

Exclusion criteria

* Patient is less than 18 years old * Patient received multiple organ transplants * Patient had an organ transplant prior to their lung transplant * Patients who received a single lung transplant * Patient less than 90 days or more than 1 year from their lung transplant * If patient has smoked 4 hours or less before breath sample or consumed alcohol (including mouthwash) 8 hours or less before breath sample

Design outcomes

Primary

MeasureTime frameDescription
Volatile Organic Compound profilethree to twelve months post-transplantThe VOCs in the breath of patients experiencing lung rejection post-transplant per bronchoscopy will be compared to lung transplant patients who are not experiencing rejection

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026